Hirudin-ähnliche Faktoren
Eine Multigenfamilie von Thrombin-Inhibitoren mit femtomolarer Affinität
Zuletzt aktualisiert: June 18, 2026
Mechanismus-Haftungsausschluss
Hirudin is not a single molecule but a family of 20+ isoforms sharing approximately 20% inter-variant homology. Three principal variants — HV1, HV2, and HV3 — wurden characterized from Hirudo medicinalis, each encoded by distinct gene loci. The 2020 Genom sequencing confirmed a multigene family under diversifying selection (Kvist et al., 2020), konsistent mit the evolutionary pressure of host hemostatic adaptation.
Molekulare Architektur
Primary Structure
65 Aminosäuren, approximately 7 kDa. The molecule consists of two functional domains: an N-terminal globular domain stabilized by three disulfide bridges (Cys6-Cys14, Cys16-Cys28, Cys22-Cys39), and a C-terminal acidic tail (residues 49-65) bearing a post-translationally sulfated tyrosine at position 63 (Tyr63-SO3).
Bivalenter Bindungsmechanismus
Hirudin simultaneously engages two thrombin sites: the N-terminal domain blocks the catalytic active site, while the C-terminal tail binds anion-binding exosite I (fibrinogen recognition site). This bridge-like bivalent interaction yields a Kd of 2 × 10⁻¹⁴ M (native, sulfated Tyr63) — the tightest non-covalent Protein-Protein interaction measured in nature.
Vergleich der Bindungsaffinität
Moderne genomische Erkenntnisse
Multigen-Familie (2020)
Kvist et al. (2020) Genom-wide analysis confirmed hirudin genes form a multigene family under positive diversifying selection, suggesting ongoing evolutionary optimization against vertebrate thrombin variants. Multiple paralogous loci encode structurally distinct isoforms.
Tandem-Hirudin (2022)
Hohmann et al. (2022) identified Tandem-Hirudin from Hirudinaria manillensis — die erste oligomeric member of the hirudin superfamily. Despite structural homology, this variant shows no thrombin-inhibitory activity, suggesting functional divergence within the family.
Novel Rekombinant (2025)
A 2025 recombinant hirudin variant achieved Ki = 0.323 nM, exceeding bivalirudin in thrombin inhibition potency. Advances in cell-free synthesis systems (Szatkowski et al., 2020) are enabling rapid prototyping of engineered variants.
Cell-Free Synthesis
Szatkowski et al. (2020) demonstrated successful cell-free Protein synthesis of functional hirudin variants, bypassing traditionell expression systems. This approach accelerates structure-activity relationship Studien and enables rapid screening of engineered analogs.
Pharmazeutische Derivate
| Wirkstoff | Hirudin-Basis | FDA | Status | Indikation |
|---|---|---|---|---|
| Lepirudin (Refludan) | HV1 (Desulfatohirudin) | 1998 | 2012 eingestellt (geringe Nachfrage; bekanntes Anaphylaxie-Risiko) | HIT-assoziierte Thrombose |
| Desirudin (Iprivask) | HV2 rekombinant | 2003 | Aktiv | TVT-Prophylaxe nach Hüftgelenkersatz |
| Bivalirudin (Angiomax) | Hirudin C-terminal + D-Phe-Pro-Arg | 2000 | Aktiv | PCI-Antikoagulation |
| Dabigatran (Pradaxa) | Hirudin-SAR — orales Peptidomimetikum | 2010 | Aktiv | Schlaganfallprävention bei Vorhofflimmern |